Showing 141-150 of 333 grants
Title | Institution | Researcher | Program | Duration | Total Award Amount |
---|---|---|---|---|---|
Investigating Combinatorial Use of Inhibitors of Focal Adhesion Kinase and PFKFB3 for Reversal of Type 1 Diabetes | Trustees of Indiana University | Jon Piganelli | Cures | 01-August-2023 to 30-June-2025 | $334.595,29 |
Restoration of immune regulation in type 1 diabetes through the synergistic action of insulin-like growth factor-1 and interleukin-2 | University of Florida | Todd Brusko | Cures | 01-September-2024 to 31-August-2026 | $500.000,00 |
Allogeneic hypoimmunogenic Pancreatic Islets for Treatment of Diabetes in the Intra-Muscular Site | The Regents of the University of California, San Francisco | Tobias Deuse | Cures | 01-August-2024 to 31-July-2026 | $799.998,40 |
Achieving immune protection in islet transplantation by combining peptide-loaded nanoparticles with conformal coating of islets | University of Kansas Medical Center Research Institute, Inc. | Hubert Tse | Cures | 01-April-2024 to 31-March-2026 | $599.998,25 |
Role of pericytes during type 1 diabetes pathogenesis | University of Miami | Luciana Mateus Goncalves | Cures | 01-March-2024 to 28-February-2027 | $259.750,00 |
Endothelial cells for islet replacement in diabetes | Stanford University | Martin Neukam | Cures | 01-April-2024 to 31-March-2027 | $251.600,00 |
Local delivery of immunomodulators to enable systemic immunosuppression-free efficient islet transplantation | The Regents of the University of California, San Francisco | Bhushan Kharbikar | Cures | 01-March-2024 to 28-February-2027 | $285.000,00 |
Identifying regulators of primary human beta cell survival and proliferation | The Regents of the University of California, San Francisco | Rebecca Lee | Cures | 01-March-2024 to 28-February-2027 | $235.025,00 |
Orthogonal engineering to suppress autoreactive T cell activation in T1D cell therapy | University of Florida | Jessie Barra | Cures | 01-March-2024 to 28-February-2027 | $285.000,00 |
Localized delivery of costimulatory inhibitors and tolerogenic stromal cells for targeted immunomodulation in beta cell replacement | University of Miami | Alice Tomei | Cures | 01-February-2024 to 31-January-2027 | $750.000,00 |